.jpeg.jpg "Sydney Stern, PhD photo")
Director of TGCT Support
TGCT Support/Life Raft Group
Baltimore, Maryland, United States
Sydney Stern is the Director of Giant Cell Tumor Programs at TGCT Support. She is also a pharmacokineticist specializing in drug development for rare diseases at the U.S. Food and Drug Administration.
Dr. Stern has spearheaded numerous data projects in the field of rare tumors, including the creation of the TGCT Registry, as well as research initiatives focused on optimizing safe starting doses in oligonucleotide-based therapeutics and evaluating pharmacodynamic biomarkers as endpoints in rare diseases. In 2019, she founded TGCT Support in collaboration with the Life Raft Group, combining her expertises as a patient-researcher with TGCT. She has served on multiple advisory committees in relation to rare diseases, such as a consensus guideline for the management of TGCT in collaboration with SPAGN. Currently, her work is dedicated to advancing targeted therapies for rare diseases on a global scale, increasing access to these therapies, and enhancing patients' medical literacy regarding rare tumors.
Dr. Stern received her doctorate in Pharmaceutical Sciences from the University of Maryland Baltimore, and a Master of Science in Statistics and Clinical Research. During her tenure, she identified and developed dual agents to mitigate doxorubicin-induced cardiotoxicity and enhance the bioavailability of cyclophosphamide for the treatment of sarcoma.
Disclosure information not submitted.
Saturday, November 16, 2024
4:30 PM – 5:30 PM PST
